SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 9 of 16
Word Count: 1494
Character Count: 9221

Document Content:

“Variable Rate Transaction” (as defined in the ELOC Purchase Agreement) with any other party, unless the Company first provides the Selling Stockholder with (i) a term sheet detailing the proposed Variable Rate Transaction (including the dollar amount, price and other terms upon which the securities are to be issued, sold or exchanged) and (ii) a three (3) trading day period for the Selling Stockholder to elect to consummate such Variable Rate Transaction with the Company. If the Selling Stockholder elects not to consummate such Variable Rate Transaction with the Company, then the references to “95%” in the definitions of both the Initial Purchase Price and the Market Price under the ELOC Purchase Agreement are automatically amended to “90%”. The ELOC Purchase Agreement also provides that an Equity Line of Credit and an at-the-market offering under the Company’s existing sales agreement are not deemed to be Variable Rate Transactions. Dilutive Effect

All shares of common stock
registered in this offering which have been or may be issued or sold by us to the Selling Stockholder under the ELOC Purchase Agreement
are expected to be freely tradable. It is anticipated that the shares of common stock registered in this offering will be sold over a
period starting on the date that the Registration Statement is declared effective. The sale by the Selling Stockholder of a significant
amount of common stock registered in this offering could cause the market price of our common stock to decline and to be highly volatile.
Sales of ELOC Shares to the Selling Stockholder, if any, will depend upon market conditions and other factors to be determined by us.
We may ultimately decide to sell to the Selling Stockholder all, some or none of the ELOC Shares.

The Selling Stockholder may
resell all, some or none of the shares of common stock held by it at any time, or from time to time, in its discretion. Therefore, sales
to the Selling Stockholder by us under the ELOC Purchase Agreement may result in substantial dilution to the interests of other holders
of our common stock. In addition, if we sell a substantial number of ELOC Shares to the Selling Stockholder, or if investors expect that
we will do so, the actual sales of ELOC Shares or the mere existence of our arrangement with the Selling Stockholder may make it more
difficult for us to sell securities in the future at a time and at a price that we might otherwise wish to effect such sales. However,
we have the right to control the timing and amount of any sales to the Selling Stockholder and we are not obligated to submit any Put
Notices under the ELOC Purchase Agreement.

The following table sets forth
the amount of gross proceeds we would receive from the Selling Stockholder from the sale of all ELOC Shares that could be issued to the
Selling Stockholder under the ELOC Purchase Agreement at varying purchase prices, without giving effect to the Beneficial Ownership Limitation
or the Exchange Cap. The presentation of this information is for illustrative purposes only. As noted above, we are not obligated to submit
any Put Notices under the ELOC Purchase Agreement.

Assumed
Average
Purchase
Price Per
Share (1) Number of Shares of
Registered Common Stock to
be Issued if Full Purchase,
Without Giving Effect to the
Beneficial Ownership
Limitation (2) Percentage of Outstanding
Common Stock After Giving
Effect to the Issuance to the Selling
Stockholder, Without Giving
Effect to the Beneficial Ownership
Limitation (3) Proceeds from the Sale
Common Stock to the Selling Stockholder Under the ELOC Purchase Agreement

(1)	For the avoidance of any doubt,
this price reflects the purchase price after calculation (i.e. after discounts to the market price of our shares) in accordance with
the terms of the ELOC Purchase Agreement.

(2)	Represents the number of Warrant
Shares issued and the number of ELOC Shares that could potentially be issued to the Selling Stockholder, in the aggregate and rounded
up, based on the applicable assumed purchase price per share, without giving effect to the Beneficial Ownership Limitation or the Exchange
Cap.

(3)	The denominator is based on
14,899,883 shares of our common stock outstanding as of May 14, 2026, adjusted to include the issuance of the number of shares of common
stock set forth in the adjacent column which we would have issued to the Selling Stockholder based on the applicable assumed purchase
price per share.

(4)	Represents the last reported
sales price of our common stock on May 13, 2026, as reported by Nasdaq, less a five percent (5%) discount and rounded up to the nearest
penny.

The ELOC Shares and Warrant
Shares will be offered and sold to the Selling Stockholder in reliance upon the exemption from registration provided by Section 4(a)(2)
of the Securities Act.

The foregoing summary of the
ELOC Purchase Agreement is qualified in its entirety by reference to the full text of the ELOC Purchase Agreement, which is incorporated
by reference as Exhibit 10.25 to the Registration Statement.

PLAN
OF DISTRIBUTION

The Selling Stockholder, including
its donees, pledgees, transferees or other successors-in-interest selling shares or interests in shares received after the date of this
prospectus from the Selling Stockholder as a gift, pledge, partnership distribution or other transfer, may from time to time sell, transfer
or otherwise dispose of any or all of the shares of common stock registered under the Registration Statement on any stock exchange, market
or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling the shares, unless it is
contractually bound not to use such methods:

●	ordinary brokerage transactions
and transactions in which the broker-dealer solicits purchasers;

●	block trades in which the broker-dealer
will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

●	purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;

●	an exchange distribution in
accordance with the rules of the applicable exchange;

●	privately negotiated transactions;

●	settlement of short sales;

●	in transactions through broker-dealers
that agree with the Selling Stockholder to sell a specified number of shares at a stipulated price per security;

●	through the writing or settlement
of options or other hedging transactions, whether through an options exchange or otherwise;

●	a combination of any such methods
of sale; or

●	any other method permitted
pursuant to applicable law.

The Selling Stockholder may
also sell the shares under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.

Broker-dealers engaged by the
Selling Stockholder may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of the shares, from the purchaser) in amounts to
be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance
with FINRA Rule 2121.

The Selling Stockholder is,
and any broker-dealer or agent that is involved in selling the shares may be deemed to be, an “underwriter” within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.
The Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the shares of common stock registered under the Registration Statement.

We are required to pay certain
fees and expenses incurred by us incident to the registration of these shares of common stock. We have agreed to indemnify the Selling
Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

We have also agreed to keep
this prospectus effective until all of the shares of common stock have been sold pursuant to this prospectus. The shares of common stock
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the shares covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state
or an exemption from the registration or qualification requirement is available and is complied with.

Compliance with the Exchange Act, including
Regulation M